公司财务表现 - Remitly Global的ROIC为2.09% WACC为4.64% ROIC与WACC比率为0.45 显示公司未能实现超过资本成本的回报 [2] - 与同业相比 Sterling Check Corp的ROIC为1.89% WACC为6.10% 比率0.31 在同行中资本使用效率最高 [3][4] - Expensify的ROIC为1.09% WACC为12.06% 比率0.09 同样未能产生超过资本成本的回报 [3] 同业比较分析 - AvidXchange Holdings的ROIC为-2.62% WACC为9.49% 比率为-0.28 显示资本使用效率极低 [2] - Flywire Corporation的ROIC为-0.77% WACC为9.76% 比率为-0.08 Blend Labs的ROIC为-20.91% WACC为10.11% 比率为-2.07 两者均存在显著的资本回报低效问题 [4] - 数字金融服务行业面临普遍挑战 多数同业公司未能实现ROIC超过WACC [2][3][4] 行业竞争格局 - 公司专注于国际汇款业务 在数字支付和汇款领域与金融科技公司存在竞争 [1] - 行业参与者包括AvidXchange Holdings、Expensify、Sterling Check Corp、Flywire Corporation和Blend Labs等多家企业 [2][3][4]

Emerald Holding, Inc. (NYSE:EEX) has a Return on Invested Capital (ROIC) of 2.91%, which is lower than its Weighted Average Cost of Capital (WACC) of 9.06%, indicating inefficiency in generating sufficient returns on investments.Comparative analysis shows that peers like Byline Bancorp, Inc. and WideOpenWest, Inc. also struggle with their ROIC to WACC ratios, whereas Hamilton Beach Brands Holding Company and Clipper Realty Inc. demonstrate more efficient capital utilization.Clipper Realty Inc. stands out wi ...

公司业务与行业定位 - Excelerate Energy专注于液化天然气解决方案 在公用事业领域与PNM Resources IDACORP Black Hills Corporation Avista Corporation及Southwest Gas Holdings等企业存在竞争关系[1] - 公司所处的公用事业领域具有稳定但竞争激烈的行业特征[1] 财务表现分析 - 公司投入资本回报率为5.21% 低于7.17%的加权平均资本成本 显示资本使用效率未达理想状态[2] - ROIC与WACC比值为0.73 虽未达行业最优水平 但优于部分同业公司[4][5] 同业比较情况 - Black Hills Corporation资本效率最高 ROIC达4.87% WACC为5.40% ROIC/WACC比值为0.90[3] - PNM Resources出现严重资本效率问题 ROIC为-122.19% 远低于其4.24%的WACC ROIC/WACC比值低至-28.82[3] - IDACORP的ROIC/WACC比值为0.65 Avista为0.81 Southwest Gas Holdings为0.59 均低于Excelerate Energy的0.73[4]

Chemung Financial Corporation (NASDAQ:CHMG) struggles with capital utilization, having a negative ROIC to WACC ratio.Investar Holding Corporation showcases exceptional efficiency with a high ROIC to WACC ratio, indicating superior capital utilization.Comparative analysis with peers reveals varying efficiencies in capital utilization across the banking sector.Chemung Financial Corporation (NASDAQ:CHMG) is a regional bank holding company based in New York. It provides a range of financial services, including ...

DoubleDown Interactive Co., Ltd. (NASDAQ:DDI) showcases a ROIC of 10.23%, significantly surpassing its WACC of 7.69%.Bragg Gaming Group Inc. and Integral Ad Science Holding Corp. struggle with negative ROICs, indicating inefficiencies in capital utilization.DoubleDown Interactive's superior ROIC to WACC ratio of 1.33 highlights its effective management and value creation for investors.DoubleDown Interactive Co., Ltd. (NASDAQ:DDI) is a prominent player in the digital gaming industry, known for its engaging s ...

Nektar Therapeutics (NASDAQ:NKTR) has a ROIC of -63.50% compared to its WACC of 11.16%, indicating inefficiencies in capital utilization.Comparatively, Alkermes plc (NASDAQ:ALKS) demonstrates strong financial performance with a ROIC of 18.03% and a WACC of 6.18%.Sangamo Therapeutics, Inc. (NASDAQ:SGMO) also faces challenges similar to Nektar, with a ROIC of -125.56% against a WACC of 8.02%.Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company that focuses on developing innovative medicines in are ...

Bridgeline Digital's ROIC is -21.51%, indicating it is not generating sufficient returns to cover its WACC of 7.83%.Despite a negative ROIC, BLIN's capital efficiency is relatively better than peers like Marin Software and Verb Technology.Carver Bancorp and NeuroMetrix also struggle with capital efficiency, but BLIN shows better management in utilizing its capital compared to most of its peers.Bridgeline Digital, Inc. (NASDAQ:BLIN) is a company that provides digital engagement solutions. It offers a suite o ...

Akebia Therapeutics, Inc. (NASDAQ:AKBA) has a Return on Invested Capital (ROIC) of 0.34% and a Weighted Average Cost of Capital (WACC) of 10.46%, indicating inefficiencies in capital utilization.Ardelyx, Inc. (NASDAQ:ARDX) shows a slightly better ROIC to WACC ratio compared to its peers, despite it being negative.FibroGen, Inc. (NASDAQ:FGEN), Karyopharm Therapeutics Inc. (NASDAQ:KPTI), Calithera Biosciences, Inc. (NASDAQ:CALA), and Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) face significant challenges in gene ...

公司业务与行业定位 - 公司专注于开发基于蛋白质的疗法 用于治疗癌症和其他严重疾病 在竞争激烈的生物技术行业运营[1] - 行业主要竞争者包括Keros Therapeutics、Kymera Therapeutics、iTeos Therapeutics、Harmony Biosciences Holdings和Vaxcyte 均致力于治疗领域的创新[1] 财务表现分析 - 公司投入资本回报率为-95.25% 远低于8.16%的加权平均资本成本 资本使用效率存在严重问题[2] - ROIC与WACC比值为-11.67 显示公司无法产生覆盖资本成本的回报[2] - 相比同业 Keros Therapeutics的ROIC为0.03% WACC为8.47% 比值为0.0035[3] - Kymera Therapeutics和iTeos Therapeutics分别呈现-29.50%和-42.54%的负ROIC 比值分别为-2.17和-4.03[3] - Vaxcyte的ROIC为-22.46% WACC为8.40% 比值为-2.67 同样显示资本使用效率低下[5] 同业比较优势 - Harmony Biosciences Holdings的ROIC达21.25% 显著高于7.65%的WACC 比值2.78为同业最高[4] - 该公司成为同业中资本使用效率最有效的企业 回报率大幅超越资本成本[4]

AudioEye, Inc. (NASDAQ:AEYE) has a ROIC of -14.04% which is significantly lower than its WACC of 6.98%, indicating inefficiency in generating returns to cover its cost of capital.ClearPoint Neuro, Inc. faces significant challenges with a ROIC of -40.55% against a WACC of 7.76%, highlighting severe inefficiencies in generating returns on invested capital.AudioEye, Inc. (NASDAQ:AEYE) is a company that focuses on digital accessibility solutions, helping businesses make their digital content accessible to indiv ...